Global Blood Therapeutics (GBT) said Friday that its once-a-day pill for sickle cell disease boosted levels of oxygen-carrying hemoglobin in a little more than half of the patients treated in a Phase 3 clinical trial — results that will allow the company to file soon for accelerated approval for the treatment in the U.S.
Some outside experts, however, cautioned that it’s far from certain whether the results will translate into better health outcomes for patients themselves, even if the clinical trial achieved its main goal.
About the Author Reprints
